SCHEMBL402047

SCHEMBL402047

CCOC(=O)c1ccc(C)[nH]1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 5/20 0.51
ALDH1A1 P00352 6/20 0.50
KDM4E B2RXH2 5/20 0.50
HPGD P15428 4/20 0.50
RAB9A P51151 3/20 0.50
SMN1; SMN2 Q16637 2/20 0.50
HSD17B10 Q99714 2/20 0.50
NPC1 O15118 2/20 0.49
MAPT P10636 2/20 0.49
MEN1 O00255 1/20 0.49
GLA P06280 1/20 0.49
GAA P10253 1/20 0.49
KMT2A Q03164 1/20 0.49
ATM Q13315 1/20 0.49
TSHR P16473 1/20 0.48
ALOX15 P16050 1/20 0.47
ESR1 P03372 2/20 0.47
L3MBTL1 Q9Y468 2/20 0.46
HTT P42858 1/20 0.46
HRH3 Q9Y5N1 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2508775 0.98 LMNA (0.50) LMNAALDH1A1KDM4EHPGDRAB9A
SCHEMBL1160497 0.90 LMNA (0.55) LMNAALDH1A1KDM4EHPGDRAB9A
SCHEMBL5747195 0.84 ALDH1A1 (0.46) LMNAALDH1A1KDM4EHPGDRAB9A
SCHEMBL358481 0.82 KDM4E (0.53) LMNAALDH1A1KDM4EHPGDRAB9A
SCHEMBL1160309 0.82 HRH3 (0.53) LMNAALDH1A1KDM4EHPGDRAB9A
SCHEMBL1231647 0.82 LMNA (0.50) LMNAALDH1A1KDM4EHPGDRAB9A
SCHEMBL21363085 0.81 HMBS (0.43) LMNAALDH1A1KDM4EHPGDRAB9A
SCHEMBL3282173 0.81 LMNA (0.49) LMNAALDH1A1KDM4EHPGDRAB9A
SCHEMBL4675224 0.81 ALOX15 (0.53) LMNAALDH1A1KDM4EHPGDRAB9A
SCHEMBL2361219 0.81 LMNA (0.50) LMNAALDH1A1KDM4EHPGDRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 226 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2948454-B1 TRIAZINE COMPOUNDS AND A PROCESS FOR PREPARATION THEREOF COUNCIL OF SCIENT & IND RES AN INDIAN REGISTERED BODY INCORPORATED UNDER THE REGISTRATION OF SOCIETI (IN) 2017-05-31 EP claimed
US-9447105-B2 Triazine compounds and a process for preparation thereof COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2016-09-20 US claimed
US-20150353566-A1 TRIAZINE COMPOUNDS AND A PROCESS FOR PREPARATION THEREOF COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2015-12-10 US claimed
EP-2948454-A1 TRIAZINE COMPOUNDS AND A PROCESS FOR PREPARATION THEREOF Council of Scientific & Industrial Research An Indian registered body incorporated under the Registration of Societies Act (Act XXI of 1860) (IN) 2015-12-02 EP claimed
WO-2014115171-A1 TRIAZINE COMPOUNDS AND A PROCESS FOR PREPARATION THEREOF COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2014-07-31 WO claimed
US-4070366-A RING ALKYLATION OF SUBSTITUTED PYRROLES, ONE STEP CANADIAN PATENTS & DEVELOPMENT LIMITED (US) 1978-01-24 US claimed
EP-4747256-A1 PARP1 INHIBITOR COMPOUNDS Duke Street Bio Limited (GB) 2026-05-27 EP disclosed
US-12528784-B2 Alkynyl-(heteroaryl)-carboxamide HCN1 inhibitors HOFFMANN-LA ROCHE INC. (US) 2026-01-20 US disclosed
EP-4654964-A1 SULFONE-1H-PYRROLE-2-CARBOXAMIDE INHIBITORS OF SARS-COV-2 NSP14 METHYLTRANSFERASE AND DERIVATIVES THEREOF The Rockefeller University (US) 2025-12-03 EP disclosed
EP-4651953-A1 COMPOSITIONS USEFUL FOR MODULATING SPLICING Skyhawk Therapeutics, Inc. (US) 2025-11-26 EP disclosed
EP-4651951-A1 COMPOSITIONS USEFUL FOR MODULATING SPLICING Skyhawk Therapeutics, Inc. (US) 2025-11-26 EP disclosed
EP-4577537-A1 SUBSTITUTED BICYCLES AS HSET INHIBITORS Merck Patent GmbH (DE) 2025-07-02 EP disclosed
CN-120091998-A Substituted bicyclic rings as HSET inhibitors 默克专利股份公司 2025-06-03 CN disclosed
WO-2005066135-A2 PYRROLE AND PYRAZOLE DAAO INHIBITORS SEPRACOR INC. (US) 2005-07-21 WO disclosed
US-20050143443-A1 Pyrrole and pyrazole DAAO inhibitors SEPRACOR INC. (US) 2005-06-30 US disclosed
WO-2005026149-A1 PYRROL DERIVATIVES WITH ANTIBACTERIAL ACTIVITY ASTRAZENECA AB (SE) 2005-03-24 WO disclosed
EP-1453789-A2 N,N'-SUBSTITUTED-1,3-DIAMINO-2-HYDROXYPROPANE DERIVATIVES Elan Pharmaceuticals, Inc. (US) 2004-09-08 EP disclosed
US-20040171881-A1 N,N'-substituted-1,3-diamino-2-hydroxypropane derivatives PHARMACIA & UPJOHN COMPANY 2004-09-02 US disclosed
WO-2003040096-A2 N, N'-SUBSTITUTED-1,3-DIAMINO-2-HYDROXYPROPANE DERIVATIVES ELAN PHARMACEUTICALS, INC. (US) 2003-05-15 WO disclosed
US-4070366-A RING ALKYLATION OF SUBSTITUTED PYRROLES, ONE STEP CANADIAN PATENTS & DEVELOPMENT LIMITED (US) 1978-01-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12528784-B2 Alkynyl-(heteroaryl)-carboxamide HCN1 inhibitors HCN1, HCN2, HCN3 LMNA 353/4885ALDH1A1 529/4885KDM4E 3387/4885
US-20050143443-A1 Pyrrole and pyrazole DAAO inhibitors DDO, DAO, SRR LMNA 4759/4885ALDH1A1 3634/4885KDM4E 1764/4885
US-20150353566-A1 TRIAZINE COMPOUNDS AND A PROCESS FOR PREPARATION THEREOF TPH2, IDO2, INMT LMNA 1199/4885ALDH1A1 2885/4885KDM4E 862/4885
US-20040171881-A1 N,N'-substituted-1,3-diamino-2-hydroxypropane derivatives BACE1, BACE2, PSEN1 LMNA 426/4885ALDH1A1 527/4885KDM4E 4309/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.